DamenJAHooftLSchuitE, et al.Prediction models for cardiovascular disease risk in the general population: systematic review. BMJ2016; 353: i2416–i2416.
3.
ConroyRMPyoralaKFitzgeraldAP, et al.Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J2003; 24: 987–1003.
4.
HuaXMcDermottRLungT, et al.Validation and recalibration of the Framingham cardiovascular disease risk models in an Australian Indigenous cohort. Eur J Prev Cardiol2017; 24: 1660–1669.
5.
PeriniWSnijderMBPetersRJ, et al.Estimation of cardiovascular risk based on total cholesterol versus total cholesterol/high-density lipoprotein within different ethnic groups: the HELIUS study. Eur J Prev Cardiol. 2019; 26: 1888–1896.
6.
GoffDCJrLloyd-JonesDMBennettG, et al.2013 ACC/AHA Guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation2014; 129: S49–S73.
7.
BoatengDAgyemangCBeuneE, et al.Cardiovascular disease risk prediction in sub-Saharan African populations – comparative analysis of risk algorithms in the RODAM study. Int J Cardiol2018; 254: 310–315.
8.
Jaspers NEM, Blaha MJ, Matsushita K, et al. Prediction of individualized lifetime benefit from cholesterol lowering, blood pressure lowering, antithrombotic therapy, and smoking cessation in apparently healthy people. Eur Heart J. Epub ahead of print 19 May 2019. DOI: 10.1093/eurheartj/ehz239.
9.
Berkelmans GFN, Gudbjornsdottir S, Visseren FLJ, et al. Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500,000 patients with type 2 diabetes mellitus. Eur Heart J. Epub ahead of print 11 January 2019. DOI: 10.1093/eurheartj/ehy839.
10.
DorresteijnJAKaasenbroodLCookNR, et al.How to translate clinical trial results into gain in healthy life expectancy for individual patients. BMJ2016; 352: i1548–i1548.
